Lilly (LLY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks
Open on Zacks
Lilly (LLY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Eli Lilly (LLY) reported $24.4 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 38.6%. EPS of $7.48 for the same period compares to $7.02 a year ago.

The reported revenue represents a surprise of +10.37% over the Zacks Consensus Estimate of $22.11 billion. With the consensus EPS estimate being $5.38, the EPS surprise was +39.03%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Lilly performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue - Cardiometabolic Health - Foundayo - Outside U.S.: $59 million versus the two-analyst average estimate of $63.08 million. Revenue- International- Humulin: $50 million versus $51.46 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -8.4% change. Revenue- International- Forteo: $25 million versus the two-analyst average estimate of $28.35 million. The reported number represents a year-over-year change of -19.1%. Revenue- International- Alimta: $8 million versus $16.35 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -52.7% change. Revenue- Cyramza (Ramucirumab /IMC-1121B)- Total: $226 million compared to the $202.04 million average estimate based on two analysts. The reported number represents a change of -7.9% year over year. Revenue - Cardiometabolic Health - Foundayo - Total: $184 million compared to the $193.1 million average estimate based on two analysts. Revenue- Jardiance (Empagliflozin/BI 10773)- Total: $1.58 billion versus $865.61 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +64.6% change. Revenue- Immunology: $1.44 billion versus $1.54 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change. Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- Total: $263 million versus the two-analyst average estimate of $274.47 million. The reported number represents a year-over-year change of -2.2%. Revenue- Taltz (Ixekizumab / LY2439821 / IL-17)- Total: $856 million versus the two-analyst average estimate of $918.2 million. The reported number represents a year-over-year change of -5.1%. Revenue- Verzenio- Total: $1.51 billion compared to the $1.54 billion average estimate based on two analysts. The reported number represents a change of +2.8% year over year. Revenue- Emgality (Galcanezumab)- Total: $186 million versus $174.74 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change.

View all Key Company Metrics for Lilly here>>>

Shares of Lilly have returned +11.3% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Eli Lilly and Company (LLY): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research